血清胱抑素C对慢加急性肝衰竭患者肾损伤的早期诊断意义

万志红; 王建军; 谢国明; 游绍莉; 刘鸿凌; 朱冰; 臧红; 辛绍杰

doi:10.3969/j.issn.1001-5256.2014.07.024

血清胱抑素C对慢加急性肝衰竭患者肾损伤的早期诊断意义

DOI: 10.3969/j.issn.1001-5256.2014.07.024

解放军三〇二医院肝衰竭诊疗与研究中心

基金项目:

首都临床特色应用研究专项(Z131107002213018)；

详细信息

中图分类号: R512.6;R575.3
计量
- 文章访问数: 2520
- HTML全文浏览量: 16
- PDF下载量: 527
- 被引次数: 0
出版历程
- 收稿日期: 2013-08-15
- 出版日期: 2014-07-20

Significance of serum cystatin C level for early diagnosis of acute kidney injury in patients with acute-on-chronic liver failure

Liver Failure Treatment and Research Center, 302 Hospital of PLA

Research funding:

摘要

摘要:
目的研究血清胱抑素C（CysC）水平对慢加急性肝衰竭（ACLF）患者急性肾损伤（AKI）的早期诊断意义。方法选取2011年8月-2012年10月于本院住院的慢性乙型肝炎相关慢加急性肝衰竭（ACLF）、慢性乙型肝炎（CHB）的患者各60例,同期60例健康者作为对照。肝衰竭患者随访至出院,动态收集患者血清。采用胶乳增强免疫比浊法测定血清CysC水平。通过绘制CysC、肌酐和血钠浓度诊断AKI的受试者工作特征曲线（ROC）,获得其曲线下面积（AUC）及最佳临界值。正态分布的计量资料,多组间比较采用单因素方差分析（One-way ANOVA）,2组间比较采用双侧t检验;否则,组间比较采用Mann-Whitney U检验。计数资料采用χ2检验。相关分析采用Pearson相关检验。AUC及最佳临界值的计算采用Medcal 12.7.1.0进行分析。结果肝衰竭患者血清CysC水平为（1050±444）ng/ml,显著高于健康对照组（638±275）ng/ml（P=0.016）和CHB组患者（661±225）ng/ml（P=0.028）。ACLF患者血清CysC水平与肌酐水平相关性不显著（r=0.31...
- 肝功能衰竭 /
- 胱抑素C /
- 急性肾损伤
Abstract:
Objective To investigate the significance of serum cystatin C (CysC) level for the early diagnosis of acute kidney injury (AKI) in patients with acute- on- chronic liver failure (ACLF) . Methods Sixty patients with chronic hepatitis B- related ACLF and 60 patients with CHB, as well as 60 healthy controls, were included in the study. The ACLF patients were followed up until discharge, and serum samples were collected during hospital stay. Serum CysC level was measured by latex- enhanced immunoturbidimetric assay. The receiver operating characteristic (ROC) curves of serum CysC, creatinine (Cr) , and sodium levels for the diagnosis of AKI were drawn, and the areas under the ROC curves (AUCs) and optimal cut- off values were determined. For normally distributed measurement data, comparison between groups was made by one- way analysis of variance, and multiple comparisons were made by two- sided t test; otherwise, comparison between groups was made by Mann- Whitney U test. Enumeration data were analyzed by chi- square test. The Pearson correlation test was used for correlation analysis. The AUCs and optimal cut- off values were calculated by Medcal 12. 7. 1. 0. Results The serum CysC level in ACLF patients was 1050 ± 444 ng /ml, which was significantly higher than those in healthy controls (638 ± 275 ng /ml, P = 0. 016) and CHB patients (661 ± 225 ng /ml, P = 0. 028) ; for ACLF patients, serum CysC level was not significantly correlated with serum Cr level (r =0.311, P >0.05) , but showed a significant positive correlation with MELD score (r =0. 529, P <0. 01) . During hospital stay, 8 (13.3%) of ACLF patients developed AKI. The multivariate logistic regression analysis indicated that serum CysC level was the independent risk factor for AKI development in ACLF patients (OR = 1. 008, P = 0. 021) . The cut- off value of serum CysC level for the early diagnosis of AKI in ACLF patients was 1210 ng /ml. Conclusion Elevated serum CysC level may provide an early prediction of AKI development in ACLF patients with a normal serum Cr level during hospital stay.
- liver failure /
- cystatin C /
- acute kidney injury

HTML全文

参考文献(18)

[1]THABUT D, MASSARD J, GANGLOFF A, et al.Model for endstage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure[J].Hepatology, 2007, 46 (6) :1872-1882.

[2]ZHU B, YOU SL, WAN ZH, et al.Determination of serum M30and M65 levels and its clinical significance in patients with HBVrelated acute-on-chronic liver failure[J].J Clin Hepatol, 2013, 29 (9) :678-680. (in Chinese) 朱冰, 游绍莉, 万志红, 等.HBV相关慢加急性肝衰竭患者血清M30、M65的检测及其临床意义[J].临床肝胆病杂志, 2013, 29 (9) :678-680.

[3]PERRONE RD, MADIAS NE, LEVEY AS.Serum creatinine as an index of renal function:new insights into old concepts[J].Clin Chem, 1992, 38 (10) :1933-1953.

[4]SJSTRM P, TIDMAN M, JONES I.Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans[J].Scand J Clin Lab Invest, 2005, 65 (2) :111-124.

[5]CHEW JSC, SALEEM M, FLORKOWSKI CM, et al.Cystatin CA paradigm of evidence based laboratory medicine[J].Clin Biochem Rev, 2008, 29 (2) :47-62.

[6]Liver failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, ChineseMedical Association.Diagnostic and treatment guidelines for liver failure[J].Chin J Hepatol, 2006, 14 (9) :643-646. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14 (9) :643-646.

[7]Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology, Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis, 2001, 19 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].传染病信息, 2001, 19 (1) :56-62.

[8]MEHTA RL, KELLUM JA, SHAH SV, et al.Acute Kidney Injury Network:report of an initiative to improve outcomes in acute kidney injury[J].Crit Care, 2007, 11 (2) :r31.

[9]SALERNO F, GERBES A, GINS P, et al.Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis[J].Gut, 2007, 56 (9) :1310-1318.

[10]CRDENAS A, GINS P.Acute-on-chronic liver failure:the kidneys[J].Curr Opin Crit Care, 2011, 17 (2) :184-189.

[11]SHARAWEY MA, SHAWKY EM, ALI LH, et al.Cystatin C:a predictor of hepatorenal syndrome in patients with liver cirrhosis[J].Hepatol Int, 2011, 5:927-933.

[12]PECO-ANTIC'A, IVANIEVIC'I, VULIC'EVIC'I, et al.Biomarkers of acute kidney injury in pediatric cardiac surgery[J].Clin Biochem, 2013, 46 (13) :1244-1251.

[13]ZHANG Z, LU B, SHENG X, et al.Cystatin C in prediction of acute kidney injury:a systemic review and meta-analysis[J].Am J Kidney Dis, 2011, 58 (3) :356-365.

[14]RENDERS E, ERLANDSEN EJ, PEDERSEN OL, et al.Serum cystatin C as an endogenous paraneter of the renal function in patients with mormal to moderately impaired kidney function[J].Clin Nephrol, 2000, 4 (3) :203-209.

[15]HOTTA O, YUSA N, MUKAIYAMA I, et al.Usefulness of serum cystatin C as a marker of the renal function;a comqarative evaluation with beta 2-microglobulin, alpha 1-microglobulin and creatinine[J].Nippon Jinzo Gakkai Shi, 1999, 41 (8) :797-803.

[16]FRANCOZ C, GLOTZ D, MOREAU R, et al.The evaluation of renal function and disease in patients with cirrhosis[J].J Hepatol, 2010, 52 (4) :605-613.

[17]ZHENG XL, WANG LZ, HE JH, et al.Diagnostic value of serum cystatin C and urotensin II for hepatorenal syndrome in patients with decompensated liver cirrhosis[J].J Clin Hepatol, 2013, 29 (8) :627-630. (in Chinese) 郑晓丽, 汪良芝, 贺建华, 等.胱抑素C、血浆尾加压素Ⅱ在失代偿肝硬化合并肝肾综合征患者中的诊断价值[J].临床肝胆病杂志, 2013, 29 (8) :627-630.

[18]BARAKAT M, KHALIL M.Serum cystatin C in advanced liver cirrhosis and different stages of the hepatorenal syndrome[J].Arab J Gastroenterol, 2011, 12 (3) :131-135.

施引文献

资源附件(0)

访问统计